Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.73M Buy
165,915
+126
+0.1% +$3.35K 3.98% 11
2026
Q2
$3.99M Buy
165,789
+135
+0.1% +$3.53K 3.28% 12
2026
Q1
$4.65M Sell
165,654
-368
-0.2% -$9.8K 4.19% 11
2025
Q4
$4.13M Buy
166,022
+1,129
+0.7% +$28.5K 3.72% 14
2025
Q3
$4.2M Buy
164,893
+281
+0.2% +$6.94K 3.78% 11
2025
Q2
$3.99M Buy
164,612
+1,924
+1% +$44.9K 3.66% 11
2025
Q1
$4.12M Buy
162,688
+16,888
+12% +$442K 4.13% 11
2024
Q4
$3.87M Buy
+145,800
New +$3.95M 3.86% 11

Other funds holding PFE

Drystone's PFE Position: Q3 2026 in Review

Drystone increased its Pfizer (PFE) stake by 0.08% in Q3 2026, buying an estimated $3.35K and bringing the position to 165,915 shares worth $4.73M. The position accounts for 3.98% of the portfolio, ranked #11.

Drystone first reported a position in PFE in Q4 2024 and has held it in 8 quarters since. 1,243 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Drystone held 165,915 shares of Pfizer worth $4.73M as of Q3 2026.
  • Drystone bought 126 Pfizer shares in Q3 2026, an estimated $3.35K.
  • Pfizer made up 3.98% of Drystone's portfolio in Q3 2026, its #11 holding.
  • Drystone first reported a position in Pfizer in Q4 2024 and has held it in 8 quarters since.
  • 1,243 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Drystone's 13F filing for Q3 2026, filed 30 Oct 2026.